Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients
Authors:
Open Access
- 1 January 2011
- journal article
- research article
- Published by Springer Nature in Journal of Immune Based Therapies and Vaccines
- Vol. 9 (1) , 7
Abstract
The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical trials, patients started vaccination 1 month after finishing first line chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high dose) was very safe. The most frequent adverse events were grade 1 or 2 injection site reactions, fever, headache and vomiting. Patients had a trend toward higher antibody response. The percent of very good responders significantly augmented and there was a faster decrease of circulating EGF. All vaccinated patients and those classified as good responders immunized with high dose at 4 sites, had a large tendency to improved survival.Keywords
This publication has 23 references indexed in Scilit:
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidenceLung Cancer, 2011
- EGFR pathway in advanced non-small cell lung cancerFrontiers in Bioscience-Scholar, 2011
- Immunotherapy in the landscape of new targeted treatments for non‐small cell lung cancerMolecular Oncology, 2009
- Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung CancerJournal of Immunotherapy, 2009
- Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose TrialJournal of Virology, 2008
- Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti–Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non–Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer VaccineClinical Cancer Research, 2008
- Safety and Immunogenicity of Tyrosinase DNA Vaccines in Patients with MelanomaMolecular Therapy, 2007
- Spatial Distribution of Tumor Vaccine Improves EfficacyThe Laryngoscope, 2003
- Regulation of the Immune Response by AntigenScience, 2001
- Enhanced Immune Priming with Spatial Distribution of Paracrine Cytokine VaccinesJournal of Immunotherapy, 1996